ne 58051 has been researched along with risedronic acid in 15 studies
| Studies (ne 58051) | Trials (ne 58051) | Recent Studies (post-2010) (ne 58051) | Studies (risedronic acid) | Trials (risedronic acid) | Recent Studies (post-2010) (risedronic acid) |
|---|---|---|---|---|---|
| 17 | 0 | 2 | 1,318 | 290 | 487 |
| Protein | Taxonomy | ne 58051 (IC50) | risedronic acid (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1104 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.1699 | |
| Farnesyl diphosphate synthase | Toxoplasma gondii | 0.074 | |
| Farnesyl diphosphate synthase | Trypanosoma cruzi | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, BN; Caldera, A; Croft, SL; Docampo, R; Grimley, JS; Heath, HT; Kendrick, H; Lewis, JC; Lira, R; Martin, MB; Moreno, SN; Oldfield, E; Urbina, JA; Yardley, V | 1 |
| Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM | 1 |
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Burzynska, A; Croft, SL; de Luca-Fradley, K; Grimley, JS; Kafarski, P; Kendrick, H; Lewis, JC; Martin, MB; Meints, GA; Oldfield, E; Olsen, JR; Sanders, JM; Van Brussel, EM | 1 |
| Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM | 1 |
| Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Blackburn, GM; Brown, RJ; Carran, J; Hounslow, AM; Rejman, D; Watts, DJ | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cao, R; Liu, YL; Oldfield, E; Wang, Y | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Clézardin, P; Ebetino, FH; Fournier, PG; Stresing, V | 1 |
1 review(s) available for ne 58051 and risedronic acid
| Article | Year |
|---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
14 other study(ies) available for ne 58051 and risedronic acid
| Article | Year |
|---|---|
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Diphosphonates; Leishmania donovani; Plasmodium falciparum; Structure-Activity Relationship; Toxoplasma; Trypanosoma brucei brucei; Trypanosoma cruzi; Vero Cells | 2001 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
Topics: Animals; Crystallography, X-Ray; Diphosphonates; Humans; Lethal Dose 50; Models, Molecular; Quantitative Structure-Activity Relationship; Quantum Theory; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Tumor Cells, Cultured | 2002 |
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid | 2003 |
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2004 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes | 2006 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
Topics: Animals; Bone Density Conservation Agents; Dictyostelium; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Microscopy; Nitrogen; Proteome; Risedronic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Fast Atom Bombardment | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries.
Topics: | 2015 |
How do bisphosphonates inhibit bone metastasis in vivo?
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Etidronic Acid; Female; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Pyridines; Risedronic Acid; Xenograft Model Antitumor Assays | 2010 |